Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

Bashinformsvyaz reported for 2023 by RAS

3/20/24 BISVP

PIK reported for 2023 by RAS

3/20/24 PIKK

Board of Directors of Inter RAO recommended that dividends be paid for 2023

3/20/24 IRAO

TCS Holding determined the parameters of the additional share issue

3/20/24 ROSB

TCS Holding determined the parameters of the additional share issue

3/20/24 T

Cherkizovo Group acquired a feed mill

3/20/24 GCHE

Slavneft-YaNOS reported for 2023 under RAS

3/20/24 JNOS

Artgen Biotech will not conduct an additional share issue in 2024

3/20/24 ABIO

Transneft reported for 2023 by RAS

3/20/24 TRNFP

Transneft reported for 2023 by IFRS

3/20/24 TRNFP